• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ALNA

    Allena Pharmaceuticals Inc.

    Subscribe to $ALNA
    $ALNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Newton, Massachusetts.

    IPO Year: 2017

    Exchange: NASDAQ

    Website: allenapharma.com

    Peers

    $DRNA
    $KNSA

    Recent Analyst Ratings for Allena Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Allena Pharmaceuticals Inc. SEC Filings

    See more
    • SEC Form SEC STAFF ACTION filed by Allena Pharmaceuticals Inc.

      SEC STAFF ACTION - Allena Pharmaceuticals, Inc. (0001624658) (Filer)

      6/12/23 2:00:02 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-Q filed by Allena Pharmaceuticals Inc.

      NT 10-Q - Allena Pharmaceuticals, Inc. (0001624658) (Filer)

      11/14/22 4:03:10 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Allena Pharmaceuticals Inc.

      25-NSE - Allena Pharmaceuticals, Inc. (0001624658) (Subject)

      9/14/22 9:52:49 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Allena Pharmaceuticals, Inc. (0001624658) (Filer)

      9/7/22 4:30:49 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Bankruptcy or Receivership, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update

      8-K - Allena Pharmaceuticals, Inc. (0001624658) (Filer)

      9/2/22 5:15:37 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Allena Pharmaceuticals, Inc. (0001624658) (Filer)

      8/24/22 4:17:01 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Allena Pharmaceuticals Inc.

      10-Q - Allena Pharmaceuticals, Inc. (0001624658) (Filer)

      8/15/22 4:47:02 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Allena Pharmaceuticals, Inc. (0001624658) (Filer)

      8/11/22 8:00:58 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Allena Pharmaceuticals, Inc. (0001624658) (Filer)

      8/4/22 4:33:48 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Allena Pharmaceuticals Inc.

      DEFA14A - Allena Pharmaceuticals, Inc. (0001624658) (Filer)

      7/13/22 4:11:55 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Allena Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Katz Richard D

      4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)

      2/2/22 4:15:22 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Brenner Louis Md

      4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)

      2/2/22 4:15:11 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Brenner Louis Md sold $32,666 worth of shares (40,328 units at $0.81) and converted options into 125,582 shares (tax withholding)

      4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)

      11/17/21 5:00:29 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Allena Pharmaceuticals, Inc.

      4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)

      6/4/21 4:00:33 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Allena Pharmaceuticals, Inc.

      4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)

      6/4/21 4:00:44 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Allena Pharmaceuticals, Inc.

      4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)

      6/4/21 4:00:14 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by SANTINI GINO

      4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)

      6/4/21 4:00:15 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Allena Pharmaceuticals, Inc.

      4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)

      6/4/21 4:00:19 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: BRENNER LOUIS MD sold $27,989 worth of Common Stock (25,215 units at $1.11) and exercised 83,721 units of Common Stock at a strike of $0.00 (tax liability)

      4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)

      5/12/21 4:45:42 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by J. Mark Fitzpatrick

      4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)

      4/8/21 2:51:09 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Allena Pharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Allena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Allena Pharmaceuticals, Inc. (0001624658) (Subject)

      2/14/23 4:09:01 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Allena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Allena Pharmaceuticals, Inc. (0001624658) (Subject)

      2/14/22 4:34:57 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Allena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Allena Pharmaceuticals, Inc. (0001624658) (Subject)

      1/28/22 1:42:29 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Allena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Allena Pharmaceuticals, Inc. (0001624658) (Subject)

      1/25/22 4:05:14 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Allena Pharmaceuticals, Inc. (0001624658) (Subject)

      2/16/21 5:06:12 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Allena Pharmaceuticals, Inc. (0001624658) (Subject)

      2/8/21 10:15:35 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Allena Pharmaceuticals Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split

      NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and outstanding common stock. The Special Meeting will now be held on August 4, 2022, at 9:00 a.m., local time via live webcast. The new record date for the

      7/12/22 4:05:00 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Versantis Appoints Mark Fitzpatrick, Seasoned Biotech Executive, as its New CEO

      - Versantis establishes wholly-owned U.S. subsidiary, Versantis, Inc. - - Current CEO, Vincent Forster, to maintain his key role as Chief Scientific Officer - Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, today announced the appointment of Mark J. Fitzpatrick as Chief Executive Officer (CEO) and member of the board of directors, effective January 1, 2022. He joins Versantis with more than 25 years of experience in the biopharma industry, primarily in senior executive roles, and will be based in the U.S. following the establishment of Versantis, Inc. He succeeds co-founder Dr. Vincent Forster, who will assume the role

      12/20/21 1:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors Allena Pharmaceuticals, Inc.

      NEWTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Mark J. Fitzpatrick to its board of directors. “Mark is an experienced industry executive, who has led financial strategy at biopharmaceutical companies across all stages of development,” said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals. “His extensive experience working with late-stage, rare disease companies will be particular

      4/7/21 8:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

          -- Reloxaliase continues to progress through ongoing pivotal Phase 3 URIROX-2 trial for enteric hyperoxaluria -- -- ALLN-346 poised to enter Phase 1 multiple-ascending dose and Phase 2a trials for hyperuricemia and gout -- -- Management team strengthened with addition of David Clark, M.D., M.R.C.P as Chief Medical Officer and Richard Katz, M.D. as Chief Financial Officer -- NEWTON, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today r

      3/9/21 7:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Allena Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease

      NEWTON, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) ("Allena" or the "Company"), a biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to treat metabolic diseases, today reported completion of enrollment of the first two cohorts of its ALLN-346 Phase 2a Study 202 in gout patients with stage 2 (cohort A) and stage 3 (cohort B) chronic kidney disease (CKD). ALLN-346, which has received Fast Track Designation from the U.S. Food and Drug Administration (FDA), is a first-in-class, non-absorbed, orally administered enzyme in development for the tr

      7/19/22 8:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split

      NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and outstanding common stock. The Special Meeting will now be held on August 4, 2022, at 9:00 a.m., local time via live webcast. The new record date for the

      7/12/22 4:05:00 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock Split

      NEWTON, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting, which was scheduled for July 5, 2022, to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and outstanding common stock. The date of the rescheduled special meeting, and the new record date for determining the

      7/5/22 7:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Announces $2.8 Million Registered Direct Offering

      NEWTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has entered into a securities purchase agreement with an investor for the issuance and sale of an aggregate of 1,436.0688 shares of its Series D Convertible Preferred Stock, and 1,436.0688 shares of its Series E Convertible Preferred Stock in a registered direct offering for an aggregate gross proceeds of approximately $2.8 million, before deducting placement agent fees and other off

      5/4/22 8:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Provides Clinical and Corporate Update

      ALLN-346, an orally administered enzyme in development for the treatment of hyperuricemia and gout, demonstrates a statistically significant reduction in serum uric acid and a well-tolerated safety profile in first cohort of patients with hyperuricemia and chronic kidney disease in the Phase 2a Study 201 Allena to host webinar to discuss the initial Study 201 data with Key Opinion Leaders Robert Terkeltaub, M.D. and David S. Goldfarb, M.D. today at 8:00 am ET; log-in information belowALLN-346 Phase 2a Study 202 is actively enrolling patients with gout and stages 2 and 3 chronic kidney disease in parallel cohorts; data from both cohorts expected in Q1 2022Company currently evaluating potenti

      1/4/22 5:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Versantis Appoints Mark Fitzpatrick, Seasoned Biotech Executive, as its New CEO

      - Versantis establishes wholly-owned U.S. subsidiary, Versantis, Inc. - - Current CEO, Vincent Forster, to maintain his key role as Chief Scientific Officer - Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, today announced the appointment of Mark J. Fitzpatrick as Chief Executive Officer (CEO) and member of the board of directors, effective January 1, 2022. He joins Versantis with more than 25 years of experience in the biopharma industry, primarily in senior executive roles, and will be based in the U.S. following the establishment of Versantis, Inc. He succeeds co-founder Dr. Vincent Forster, who will assume the role

      12/20/21 1:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals to Participate in the Stifel 2021 Virtual Healthcare Conference

      NEWTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today announced that company management will present at the Stifel 2021 Virtual Healthcare Conference being held November 15th-17th 2021. Please see the details for the presentation below: Stifel 2021 Virtual Healthcare ConferenceDate:8:40 a.m. ETTime:Wednesday, November 17th, 2021Webcast:https://wsw.com/webcast/stifel58/alna/2067120 Management will also be available for 1x1 meetings. If you woul

      11/15/21 4:05:00 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress

      ALLN-346, a first-in-class, non-absorbed, orally administered enzyme in development for the treatment of hyperuricemia and gout in the setting of advanced chronic kidney disease, receives Fast Track Designation from FDA Two Phase 2a trials for ALLN-346 enrolling patients with gout and chronic kidney disease; initial data expected in Q1 2022First interim analysis for URIROX-2 Phase 3 trial of reloxaliase for the treatment of enteric hyperoxaluria planned for Q1 2022Registered direct offering completed in Q3 raising gross proceeds of $28.0 million NEWTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) ("Allena" or the "Company"), a late-stage biopharma

      11/10/21 4:05:00 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients With Gout and Advanced Chronic Kidney Disease

      - Novel oral therapeutic candidate ALLN-346 targets uric acid in the intestinal tract - - Patients with gout and CKD have a serious condition with an unmet need for urate-lowering–therapies – -Two Phase 2a studies currently enrolling patients with hyperuricemia and CKD - - Initial bioactivity data expected in late 2021 or early 2022 - NEWTON, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) ("Allena" or the "Company"), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today announced that it

      11/3/21 8:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346

      - Fourteen-day study focused on high unmet need in patients with gout and chronic kidney disease - - Novel therapeutic candidate targets uric acid in the GI tract - - Initial data expected in late 2021 or early 2022 - NEWTON, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) ("Allena" or the "Company"), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today reported that it has dosed the first patient in a second Phase 2a trial of ALLN-346 (the ALLN-346 202 Trial), a novel, orally-

      9/29/21 8:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Allena Pharmaceuticals Inc. Financials

    Live finance-specific insights

    See more
    • Allena Pharmaceuticals Provides Clinical and Corporate Update

      ALLN-346, an orally administered enzyme in development for the treatment of hyperuricemia and gout, demonstrates a statistically significant reduction in serum uric acid and a well-tolerated safety profile in first cohort of patients with hyperuricemia and chronic kidney disease in the Phase 2a Study 201 Allena to host webinar to discuss the initial Study 201 data with Key Opinion Leaders Robert Terkeltaub, M.D. and David S. Goldfarb, M.D. today at 8:00 am ET; log-in information belowALLN-346 Phase 2a Study 202 is actively enrolling patients with gout and stages 2 and 3 chronic kidney disease in parallel cohorts; data from both cohorts expected in Q1 2022Company currently evaluating potenti

      1/4/22 5:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 Million

      NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 10,400,000 shares of common stock of the Company, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 4, 2020, subject to satisfact

      12/1/20 9:47:45 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Announces $10.0 Million Bought Deal Offering

      NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 8,000,000 shares of common stock of the Company, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 4, 2020, subject to sa

      12/1/20 5:00:00 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Announces Appointment of David J. Clark, M.D., M.R.C.P. as Chief Medical Officer

      NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of David J. Clark, M.D., M.R.C.P, as Chief Medical Officer, effective immediately. Dr. Clark succeeds Annamaria Kausz, M.D., who will transition to supporting the company in an advisory capacity. “We are delighted to welcome David to Allena,” said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals. “Over the course of his career, David has

      12/1/20 8:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care